Effective Brief, Low-impact, High-intensity Osteogenic Loading in Postmenopausal Osteoporosis

Osteoporosis is characterized by reduced bone mineral density (BMD) and disrupted microarchitecture estimated by trabecular bone score (TBS), resulting in increased bone fracture risk. "Osteostrong®" is a bone-strengthening system implementing 4 devices and incorporating brief (10-minute), weekly, low-impact, and high-intensity osteogenic loading exercises. We evaluated the efficacy of the Osteostrong® intervention in postmenopausal osteoporotic women. 147 postmenopausal osteoporotic women were separated into two groups: Group A comprised 74 women receiving Osteostrong® intervention (mean age 58.8 years, 56.6-61 years 95% CI), and was subdivided into G1 receiving no antiresorptive medication, and G2 on such medication. Group B comprised 73 women that received no Osteostrong® intervention (mean age 61.8 years, 59.4-64.1 95% CI) and was subdivided into G3 on no antiresorptive therapy, and G4 on such treatment. All participants underwent a physical examination and had an assessment for secondary osteoporosis. Dual-energy X-ray absorptiometry (DXA) examinations (Horizon W [S/N 300472M]) were performed at the time of trial inclusion and 12 months later. Statistically significant increases were observed in the following parameters: i) BMD of the lumbar spine (L1-L4) in G1(p=0.0039), G2(p<0.001), and G4(p=0.0059): ii) TBS in G2(p=0.0078): iii) BMD of the right femoral neck in G1(p=0.0382) and G4(p=0.032): iv) BMD of the left femoral neck G2(p=0.0089) and in G4(p=0.0498) and total femur in G2(p=0.0162). Osteostrong® improved BMD of the lumbar spine in women with osteoporosis both off and on antiresorptive treatment. Furthermore, Osteostrong® enhanced the effect of antiresorptive therapy on BMD and TBS of the spine, hip and femoral neck.